UK Government and Oxford Nanopore Forge Partnership to Advance Genomics in the NHS, Enhancing Patient Care and Biosecurity

HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

Home
/
update
/
details

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

NextEdge Admin

31 Oct 2024

2 min 40 sec

Telo Genomics Corp. , a biotech leader in telomere-based diagnostic technology, has extended its collaboration with Mayo Clinic, Minnesota, to advance its innovative prognostic tests for multiple myeloma (MM) patients. The partnership, initiated in 2020, initially focused on developing and validating TeloViewSMM, a test for patients with smoldering multiple myeloma (SMM), which is a precursor stage of MM. The TeloViewSMM test stratifies SMM patients by risk of progression to active MM, allowing high-risk patients to seek timely treatment and low-risk patients to avoid unnecessary therapies. A non-invasive blood-based test, TeloViewSMM is now an approved Laboratory Developed Test (LDT) on Telo’s CAP/CLIA and ISO 15189 accredited testing menu, with a projected market of over 500,000 tests per year.

The amended agreement adds Mayo Clinic’s participation in Telo's SMART (Physician Experience Program), using TeloViewSMM for real-world clinical application. The expansion also includes validation of TeloViewNDMM, a test designed for newly diagnosed MM (NDMM) patients, to assess the likelihood of relapse within a year while on first-line therapy. TeloViewNDMM addresses a critical clinical need, as over 50% of NDMM patients relapse within the first 12 months, with treatment costs ranging from $100,000 to $150,000 per year. By identifying patients at high risk of relapse, TeloViewNDMM enables physicians to adjust therapies preemptively, reducing the likelihood of relapse and associated costs.

With approximately 35,000 NDMM patients in the U.S. annually and 180,000 individuals living with MM, Telo’s tests present a total addressable market exceeding 800,000 tests per year. This extended partnership marks a significant step in Telo’s commercialization pathway, with potential to improve patient outcomes while addressing the economic burden of MM treatment.